MedTrace Logo

The Neurocognitive Sub-study of Encore1

NCT01516060 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2013-09-19

No results posted yet for this study

Summary

The purpose is to investigate whether HIV and HIV medication can affect certain areas of brain function. This study will look at possible changes in brain function including memory, concentration and thought processes to see if there are any differences between the two doses of efavirenz used in the Encore1 study and also the level of efavirenz in the blood

Conditions

Interventions

DRUG

Efavirenz

400mg qd; 2 x 200mg

DRUG

Efavirenz

600mg qd; 3 x 200mg qd

Sponsors & Collaborators

  • The HIV Netherlands Australia Thailand Research Collaboration

    collaborator OTHER

  • Kirby Institute

    lead OTHER_GOV

Principal Investigators

  • Rebekah Puls · Kirby Institute

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01516060 on ClinicalTrials.gov